معرفی
Dr Will Brown is a Senior Research Associate at the University of Cambridge, affiliated with the Department of Clinical Neurosciences within the School of Clinical Medicine. He serves as an Honorary Consultant Neurologist specializing in multiple sclerosis and other neuroimmunological conditions. As an NIHR Advanced Fellow, Dr Brown leads the Personalised Treatments in Multiple Sclerosis research group, focusing on using Big Data to reduce disability in MS patients. He is also a visiting research fellow at the Clinical Outcomes Research Group, University of Melbourne.
Dr Brown's research primarily focuses on reducing disability in multiple sclerosis through three main approaches: using real-world data to optimize existing disease-modifying therapies, running remyelination trials with novel imaging outcomes, and developing IT solutions to personalize MS care. His work on the CCMR-One remyelination trial with Alasdair Coles has been particularly influential in the field. Collaborating with Tomas Kalincik, he has demonstrated the long-term benefits of high-efficacy therapy for MS, especially when used early in the disease course.
Analysis of Dr Brown's recent publications reveals a strong emphasis on remyelination strategies, particularly with bexarotene, and the use of advanced MRI techniques to monitor treatment effects. His work increasingly incorporates AI and machine learning for personalized treatment prediction. A significant thread throughout his research is challenging conventional treatment paradigms, as evidenced by his findings that even non-disabling relapses predict future disability, questioning current European treatment guidelines.
- NIHR Advanced Fellow
- Senior Research Associate, University of Cambridge
- Honorary Consultant Neurologist
- Visiting Research Fellow, University of Melbourne
Dr Brown supervises several students including PhD candidates Courtney Kremler and Daniela Soares Régua, and NIHR Academic Clinical Fellow Cyrus Daruwalla. His research team comprises clinical research managers, administrators, and collaborators working across multiple institutions. His funding portfolio includes support from the MS Society, NIHR Cambridge Biomedical Research Centre, Roche, Sanofi, Novartis, and Biogen, reflecting the translational nature of his work from basic science to clinical implementation.
